Reuters -- Oncothyreon Inc posted a wider second-quarter net loss due to a non-cash charge and lower revenue resulting from the transfer of manufacturing activities for Stimuvax cancer vaccine to Merck KGaA in Dec 2008.
Reuters -- Oncothyreon Inc posted a wider second-quarter net loss due to a non-cash charge and lower revenue resulting from the transfer of manufacturing activities for Stimuvax cancer vaccine to Merck KGaA in Dec 2008.
